(1) Background: Scleroderma (Sc) is a rare connective tissue disease classified as an
autoimmune disorder. The pathogenesis of this disease is not fully understood.(2) Methods …

Background Systemic sclerosis-associated interstitial lung disease (ILD) carries a high
mortality risk; expert guidance is required to aid early recognition and treatment. We aimed …

The assessment of disease activity in systemic sclerosis (SSc) is challenging owing to its
heterogeneous manifestations across multiple organ systems, the variable rate of disease …

Systemic sclerosis (SSc) is a complex, multiorgan, autoimmune disease. Lung fibrosis
occurs in∼ 80% of patients with SSc; 25% to 30% develop progressive interstitial lung …

Systemic sclerosis (SSc) is a progressive and often devastating disease characterized by
autoimmune dysfunction, vasculopathy, and fibrosis. Interstitial lung disease (ILD) is …

Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by dysregulation of
the immune system, vascular damage, and fibrosis of the skin and internal organs. Patients …

Objective To quantify the burden of interstitial lung disease (ILD) in SSc. Methods Clinical
data for SSc patients enrolled in the Australian Scleroderma Cohort Study were linked with …

Classification of SSc-ILD has shifted to a personalized approach that considers an individual
patient's probability of progressive disease through identification of risk factors …

Abstract Objectives Treatments for SSc-associated interstitial lung disease (SSc-ILD) differ in
attributes, ie mode of administration, adverse events (AEs) and efficacy. As physicians and …

Early diagnosis of systemic sclerosis-related interstitial lung disease (SSc-ILD) is important
to enable treatment to be administered with minimal delay. However, diagnosing SSc-ILD is …